- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01546883
Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation (DEPAF)
Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial fibrillation (AF) is one of the most common cardiac arrhythmia in medical practice in both the clinical and hospital settings. In addition to a three-fold increase in the risk of mortality, AF patients are at an increased risk of developing a stroke. This risk increased from 6.7% for those who are 50-59 years of age to 36.2% for those between 80-89 years of age. One of the most serious complications of AF is thromboembolism (TE), including both Transient Ischemic Attack (TIA) and stroke, which can be fatal or disabling in many patients and is associated with either type of AF - recurrent or persistent. Image-based methods of risk-stratification and clinical scoring systems, such as the CHADS2 score, have the potential to advance our understanding of the mechanisms governing AF recurrence as well as thrombus formation and can improve our ability to prevent these potentially devastating complications.
Treatments for AF include antiarrhythmic drug therapy, anticoagulation, catheter ablation, and cardioversion, all of which have been thoroughly studied. Anticoagulation is undisputably effective in preventing strokes in patients with AF, reducing the incidence of stroke by 3 fold in high-risk patients. Pradaxa® (Dabigatran etexilate) is a new oral anticoagulant that was approved by the FDA on October 19, 2010 for reducing the risk of stroke and systemic embolism in patients with non-valvular AF. Pradaxa is a direct and reversible inhibitor of thrombin, the penultimate protease in the coagulation process. Thrombin converts fibrinogen to fibrin, which participates in forming the matrix of blood clots. Pradaxa® inhibits formation of thrombus by inhibiting the conversion of fibrinogen to fibrin. Prior to approval of Pradaxa®, warfarin has been the only other oral anticoagulant available in the US for reducing the risk of stroke associated with AF, but its use is limited because of a number of undesirable characteristics. Recently, the RE-LY study showed Pradaxa® 150mg bid was statistically significantly superior to warfarin in reducing the risk of strokes in patients with AF, although there was no statistically significant difference in risk of hemorrhage between warfarin and Pradaxa®. Pradaxa® will be used for its approved indication in this study.
The link between AF and stroke is complex but remodeling of the left atrium (LA) may play a central role. Atrial remodeling refers to any persistent change in atrial structure and function. Fibrosis, an extensive deposition of extracellular matrix components (specifically collagen and fibronectin), is the major causative component of structural remodeling of LA. AF promotes fibrosis and this structural remodeling in turn leads to increased heterogeneity of electrical conduction in the LA which can contribute to AF progression. Late gadolinium enhancement magnetic resonance imaging (LGE-MRI), is a noninvasive technique that allows us to detect and quantify structural remodeling of the LA tissue in patients with AF . Changes in the composition of LA tissue is detected by LGE-MRI based on the delayed enhancement property of the gadolinium-based contrast agent, whose slow washout kinetics relative to normal surrounding tissue, can be quantified as increased fibrosis (structural remodeling of myocardium prior to any ablation) or scar (inflammation and tissue remodeling post ablation). Preliminary findings from our lab demonstrate a significantly larger amount of atrial remodeling / fibrosis detected using LGE-MRI in those patients with strokes compared to those without.
Thrombin (the protease inhibited by Pradaxa®), also is a potent mitogen for connective-tissue producing cells which are prone to developing fibrosis and a chemoattractant for fibroblasts, thus playing an important role in development of tissue fibrosis. Bogatkevich et al. recently demonstrated Pradaxa restrained fibrotic events in lung fibroblasts, suggesting that thrombin inhibition could be an effective strategy for inhibiting fibrosis in other organs, including the heart.
We suggest the characteristics of the fibrosis that we quantify in the left atrium will be similar to the fibrosis seen in the other organs such as lungs, skin and kidney. We hypothesize that Pradaxa will inhibit left atrial structural remodeling (measured as percent fibrosis) associated with AF.
In this study, we plan to study the effect of Pradaxa on remodeling of left atrial structure (measured as percent fibrosis) as detected by LGE-MRI.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with all types of non-valvular AF (includes paroxysmal, persistent and permanent AF)
- Candidate for anticoagulation therapy
- No contra-indication for LGE-MRI
- Patients age 18 and older
- Patients who are able to provide informed consent to participate in the study
Exclusion Criteria:
- Patients who have already undergone an atrial fibrillation ablation procedure.
- Patients with active contra-indications to any anticoagulant agent.
- Other major bleeding disorders or risk factors that would place the patient at risk of bleeding.
- Recent surgery (within 30 days).
- Renal insufficiency, severe kidney disorders/diseases, GFR < 30mg/dL (Gadolinium contraindication).
- Advanced liver disease.
- Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.
- Pregnant, planning to be become pregnant or nursing women
- Individuals who are unable to provide informed consent
- Contraindicated for Pradaxa® .
- Patients the Investigators feel are inappropriate for the study
- Patients who cannot give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dabigatran
Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
|
150mg bid or 75mg bid for a period of one year
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Fibrosis
Time Frame: MRI at baseline and MRI at 12 months post-enrollment
|
We will measure the change in percentage of fibrosis over a one-year period when drug is taken.
We will calculate the results as percentage of fibrosis measured using MRI at 12 months minus the percentage of fibrosis measured using MRI at baseline to clarify if there is a decrease in fibrosis in the one year period.
|
MRI at baseline and MRI at 12 months post-enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nassir F Marrouche, MD, FHRS, University of Utah, CARMA center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB # 43119
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Spain, Belgium, Australia, Germany, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on Dabigatran etexilate (Pradaxa)
-
Boehringer IngelheimCompleted
-
Irina ErmolaevaRecruitingChronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)Russian Federation
-
Boehringer IngelheimCompletedAtrial FibrillationUnited States
-
Boehringer IngelheimCompletedAtrial FibrillationTaiwan
-
Boehringer IngelheimCompleted
-
The University of Hong KongRecruiting
-
BayerCompletedHot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenGermany
-
Boehringer IngelheimCompletedAtrial FibrillationKorea, Republic of
-
Vanderbilt University Medical CenterBoehringer IngelheimCompletedAtrial Fibrillation | Atrial FlutterUnited States
-
Boehringer IngelheimWithdrawnVenous ThromboembolismSweden, Spain, Germany, Netherlands